Dr Peter Chiu is currently an Associate Professor of the Chinese University of Hong Kong. He has primary interests in prostate cancer and benign prostatic hyperplasia. For prostate cancer, he has conducted studies in novel diagnostic modalities including blood biomarker prostate health index (phi), urine biomarker spermine, and transperineal MRI-Ultrasound fusion biopsy. He is the principal investigator of SMART trial, a multicentre randomized controlled trial in comparing MRI prostate pathway and extended transperineal prostate biopsy pathway in the diagnosis of significant prostate cancer. He is also leading a study on using biomarkers and MRI for prostate cancer screening in Hong Kong as part of the CUHK Jockey club multi-cancer screening program.

Dr Chiu was involved in the initiation of focal therapy service (HIFU and Cryotherapy) for prostate cancer in Hong Kong, and is the principal investigator of a phase 2 clinical trial on Targeted Microwave Ablation (TMA) for prostate cancer. For treatment of benign prostatic hyperplasia, he has conducted research in water vapour thermal therapy (REZUM), prostate artery embolization (PAE) and photoselective vaporization of prostate (PVP). He has received numerous research funding and has published more than 90 articles in peer-reviewed journals including European Urology, European Urology Oncology, Journal of Urology, BJU International, and Prostate Cancer and Prostatic diseases.

Dr Chiu is currently the President of the Hong Kong Urological Association (HKUA)